Related Experiment Video
Updated: Dec 20, 2025
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
10.2K
Interpretation of Cytochrome P-450 Inhibition and Induction Effects From Clinical Data: Current Standards and
Stephen M Stout1, Carrie W Nemerovski1, Daniel S Streetman1
1Wolters Kluwer Clinical Effectiveness, Hudson, Ohio, USA.
Clinical Pharmacology and Therapeutics
|May 27, 2020
Summary
Classifying cytochrome P-450 (CYP) enzyme modifiers is complex. A new approach clarifies CYP inhibitor and inducer categorization, improving drug interaction management and patient safety.
Area of Science:
- Pharmacology and Drug Metabolism
Background:
- Cytochrome P-450 (CYP) enzyme activity modifiers are classified as strong, moderate, or weak inhibitors or inducers.
- These classifications guide drug interaction management recommendations, influencing dosing and co-administration strategies.
- Ambiguity in CYP categorization can lead to suboptimal or potentially harmful clinical decisions.
Purpose of the Study:
- To review current criteria for assigning CYP inhibitor and inducer categories.
- To identify factors contributing to ambiguous or variable CYP categorizations.
- To propose a data interpretation approach for consistent CYP categorization under uncertainty.
Main Methods:
- Review of existing criteria for CYP inhibitor and inducer classification.
- Analysis of common issues leading to inconsistent categorization.
- Development and application of a novel data interpretation framework.
Main Results:
- The proposed approach addresses limitations in published data and inconsistent findings.
- Application to over 1,000 CYP reviews resulted in clear categorization in nearly all instances.
- This method enhances the reliability of classifying agents affecting CYP enzyme activity.
Conclusions:
- A systematic approach to interpreting data under uncertainty improves CYP categorization accuracy.
- Clearer CYP classifications can mitigate risks associated with inadequate or excessive drug interaction management.
- The proposed framework offers a practical solution for standardizing drug interaction potential assessments.
Related Concept Videos
01:25Pharmacokinetics: Drug–Drug Interactions
261
Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
261
01:26Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
152
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
152
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
128
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
128
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
117
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
117
01:16Bioequivalence Data: Statistical Interpretation
131
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
131
01:17Drug Metabolism: Phase I Reactions
4.4K
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...
4.4K